Protocol Ledger

NCT05780541 · Phase III · TERMINATED

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Interventional Phase III clinical trial protocol NCT05780541 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-15 Enrollment: 58 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05780541
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)58 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05780541
Protocol FieldVerified Registry Value
NCT IdentifierNCT05780541
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment58 participants (ACTUAL)
Registered Start Date2021-09-15
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05780541
Hospital Research SiteLocationSite Profile
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->
UC Davis Comprehensive Cancer CenterSacramento, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI